

**Exhibit 1**  
**MINDRAY MEDICAL INTERNATIONAL LIMITED**  
**CONDENSED CONSOLIDATED BALANCE SHEETS**  
(In thousands of US dollars)

	As of December 31, 2013 US\$ (Note 1)	As of March 31, 2014 US\$ (unaudited)
<b>ASSETS</b>		
Current assets:		
Cash and cash equivalents (Note 2)	385,224	419,820
Restricted cash (Note 3)	759	14,632
Short-term investments (Note 2)	847,041	611,027
Accounts receivable, net	220,228	182,226
Inventories	138,808	158,613
Value added tax receivables	10,225	14,208
Other receivables	21,512	21,682
Prepayments and deposits	14,310	17,340
Deferred tax assets, net	9,585	10,429
Total current assets	1,647,692	1,449,977
Restricted cash, non-current (Note 3)	17,453	10,035
Other assets	10,755	10,635
Accounts receivables, net, non-current	1,389	573
Advances for purchase of plant and equipment	18,919	20,544
Property, plant and equipment, net	324,710	338,199
Land use rights, net	59,463	58,875
Intangible assets, net	181,077	176,446
Goodwill	242,476	253,097
Total assets	2,503,934	2,318,381
<b>LIABILITIES AND EQUITY</b>		
Current liabilities:		
Short-term bank loans	260,000	210,000
Notes payable	10,945	10,260
Accounts payable	93,673	87,697
Advances from customers	28,240	31,456
Salaries payable	91,220	48,330
Other payables and current liabilities	118,951	116,351
Purchase consideration payable	20,457	29,412
Income taxes payable	20,721	23,540
Other taxes payable	12,832	7,233
Total current liabilities	657,039	564,279
Long-term bank loans	215,703	215,247
Other long-term liabilities	7,222	9,090
Deferred tax liabilities, net	45,812	47,672
Total liabilities	925,776	836,288
Commitments and contingencies		
Shareholders' equity:		
Ordinary shares	15	15
Additional paid-in capital	521,617	451,410
Retained earnings	865,676	842,603
Accumulated other comprehensive income	150,432	136,128
Treasury stock at cost	(18,792)	(8,760)
Total shareholders' equity	1,518,948	1,421,396
Non-controlling interests	59,210	60,697
Total equity	1,578,158	1,482,093
Total liabilities and equity	2,503,934	2,318,381

- (1) Financial information is extracted from the audited financial statements included in the Company's 2013 annual report on Form 20-F.
- (2) In respect of cash and cash equivalents and short-term investments, there is an aggregate compensating balance arrangement of \$241,500 and \$189,000 as of December 31, 2013 and March 31, 2014, respectively in relation to the drawings of certain bank loans.
- (3) Restricted cash are mainly those purchase consideration in connection with our acquisitions being held on escrow accounts.

**Exhibit 2****MINDRAY MEDICAL INTERNATIONAL LIMITED**  
**CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS**  
**(In thousands of US dollars, except share and per share amounts)**

	Three months ended March 31,	
	2013	2014
	US\$ (unaudited)	US\$ (unaudited)
Net revenues		
- <i>China</i>	111,332	115,828
- <i>International</i>	130,771	148,943
Net revenues	242,103	264,771
Cost of revenues	(103,038)	(118,751)
Gross profit	139,065	146,020
Selling expenses	(47,157)	(54,796)
General and administrative expenses	(26,584)	(29,813)
Research and development expenses	(26,328)	(30,143)
Income from operations	38,996	31,268
Other income, net	78	1,809
Interest income	7,687	10,779
Interest expense	(972)	(2,395)
Income before income taxes and non-controlling interests	45,789	41,461
Income tax benefits (provision)	12,934	(4,500)
Net income	58,723	36,961
Less: Net income attributable to non-controlling interests	(1,299)	(1,323)
Net income attributable to the Company	57,424	35,638
Basic earnings per share	0.49	0.30
Diluted earnings per share	0.48	0.30
Shares used in the computation of:		
Basic earnings per share	118,181,156	116,854,637
Diluted earnings per share	120,724,275	118,270,656

**Exhibit 3**
**MINDRAY MEDICAL INTERNATIONAL LIMITED**  
**CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS**  
(In thousands of US dollars)

	Three months ended March 31,	
	2013	2014
	US\$ (unaudited)	US\$ (unaudited)
<b>Cash flow from operating activities:</b>		
Net income	58,723	36,961
Adjustments to reconcile net income to net cash provided by operating activities	15,310	27,864
Changes in assets and liabilities, net of effects of acquisitions	(31,643)	(45,159)
<b>Net cash provided by operating activities</b>	<b>42,390</b>	<b>19,666</b>
<b>Cash flow from investing activities:</b>		
Acquisition cost of subsidiaries, net of cash received	(3,839)	(2,206)
Capital expenditures	(20,042)	(27,875)
Decrease (Increase) in restricted cash and restricted investment	5,399	(6,455)
Proceeds from sale of short-term investments	109,261	241,964
Increase in short-term investments and changes in other investing activities	(191,805)	(12,965)
<b>Net cash (used in) provided by investing activities</b>	<b>(101,026)</b>	<b>192,463</b>
<b>Cash flow from financing activities:</b>		
Repayment of bank loan	—	(50,000)
Proceeds from bank loans	60,000	—
Dividend paid	(59,070)	(58,711)
Proceeds from exercise of options	6,754	345
Repurchase of ordinary American depositary shares	—	(68,029)
Cash paid to acquire a non-controlling interest	—	(445)
Cash contribution from a non-controlling interest	—	239
<b>Net cash provided by (used in) financing activities</b>	<b>7,684</b>	<b>(176,601)</b>
<b>Net (decrease) increase in cash and cash equivalents</b>	<b>(50,952)</b>	<b>35,528</b>
Cash and cash equivalents, beginning of period	247,859	385,224
Effect of exchange rate changes on cash and cash equivalents	(1,163)	(932)
<b>Cash and cash equivalents, end of period</b>	<b>195,744</b>	<b>419,820</b>

**Exhibit 4**
**MINDRAY MEDICAL INTERNATIONAL LIMITED**
**RECONCILIATIONS OF NON-GAAP RESULTS OF OPERATIONS MEASURES TO THE NEAREST COMPARABLE GAAP MEASURES**
**(In thousands of US dollars, except share and per share amounts)**

	Three months ended March 31,	
	2013	2014
	(unaudited)	(unaudited)
	US\$	US\$
<b>Non-GAAP net income attributable to the Company</b>	<b>64,570</b>	<b>46,054</b>
<i>Non-GAAP net margin</i>	<i>26.7%</i>	<i>17.4%</i>
Amortization of acquired intangible assets	(2,602)	(3,447)
Deferred tax impact related to acquired intangible assets	206	615
Share-based compensation	(4,750)	(7,584)
GAAP net income attributable to the Company	57,424	35,638
<i>GAAP net margin</i>	<i>23.7%</i>	<i>13.5%</i>
Non-GAAP basic earnings per share	0.55	0.39
Non-GAAP diluted earnings per share	0.53	0.39
GAAP basic earnings per share	0.49	0.30
GAAP diluted earnings per share	0.48	0.30
Shares used in computation of:		
Basic earnings per share	118,181,156	116,854,637
Diluted earnings per share	120,724,275	118,270,656
<b>Non-GAAP operating income</b>	<b>46,348</b>	<b>42,299</b>
<i>Non-GAAP operating margin</i>	<i>19.1%</i>	<i>16.0%</i>
Amortization of acquired intangible assets	(2,602)	(3,447)
Share-based compensation	(4,750)	(7,584)
GAAP operating income	38,996	31,268
<i>GAAP operating margin</i>	<i>16.1%</i>	<i>11.8%</i>
<b>Non-GAAP gross profit</b>	<b>140,714</b>	<b>148,124</b>
<i>Non-GAAP gross margin</i>	<i>58.1%</i>	<i>55.9%</i>
Amortization of acquired intangible assets	(1,467)	(1,931)
Share-based compensation	(182)	(173)
GAAP gross profit	139,065	146,020
<i>GAAP gross margin</i>	<i>57.4%</i>	<i>55.1%</i>
<b>Non-GAAP selling expenses</b>	<b>(44,906)</b>	<b>(52,174)</b>
<i>Non-GAAP as % of total net revenues</i>	<i>18.5%</i>	<i>19.7%</i>
Amortization of acquired intangible assets	(1,135)	(1,516)
Share-based compensation	(1,116)	(1,106)
GAAP selling expenses	(47,157)	(54,796)
<i>GAAP as % of total net revenues</i>	<i>19.5%</i>	<i>20.7%</i>
<b>Non-GAAP general and administrative expenses</b>	<b>(24,158)</b>	<b>(24,562)</b>
<i>Non-GAAP as % of total net revenues</i>	<i>10.0%</i>	<i>9.3%</i>
Share-based compensation	(2,426)	(5,251)
GAAP general and administrative expenses	(26,584)	(29,813)
<i>GAAP as % of total net revenues</i>	<i>11.0%</i>	<i>11.3%</i>
<b>Non-GAAP research and development expenses</b>	<b>(25,302)</b>	<b>(29,089)</b>
<i>Non-GAAP as % of total net revenues</i>	<i>10.5%</i>	<i>11.0%</i>
Share-based compensation	(1,026)	(1,054)
GAAP research and development expenses	(26,328)	(30,143)
<i>GAAP as % of total net revenues</i>	<i>10.9%</i>	<i>11.4%</i>

---

**Exhibit 5****MINDRAY MEDICAL INTERNATIONAL LIMITED****RECONCILIATION OF GAAP NET INCOME TO EARNINGS BEFORE INTEREST, TAXES,  
DEPRECIATION AND AMORTIZATION****(In thousands of US dollars)**

	Three months ended March 31,	
	2013	2014
	US\$ (unaudited)	US\$ (unaudited)
GAAP net income attributable to the Company	57,424	35,638
Interest income	(7,687)	(10,779)
Interest expense	972	2,395
Income tax (benefits) provision	(12,934)	4,500
Earnings before interest and taxes ("EBIT")	37,775	31,754
Depreciation	7,776	8,628
Amortization	4,277	5,579
Earnings before interest, taxes, depreciation, and amortization ("EBITDA")	49,828	45,961